BioNTech SE (BNTX) EBITDA (2018 - 2025)

BioNTech SE (BNTX) has 8 years of EBITDA data on file, last reported at -$375.8 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 336.63% year-over-year to -$375.8 million; the trailing twelve-month figure through Dec 2025 stood at -$1.6 billion (down 9.74% YoY), and the FY2025 full-year result was -$1.6 billion, down 13.02% from the prior year.
• EBITDA declined to -$375.8 million in Q4 2025, from -$54.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $6.1 billion in Q1 2022 to a low of -$1.0 billion in Q2 2024.
• A 5-year average of $1.7 billion and a median of $362.5 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 5574.02% in 2021 and sank 575.48% in 2025, its largest moves.
• Tracing BNTX's EBITDA over 5 years: stood at $5.4 billion in 2021, then sank by 37.51% to $3.4 billion in 2022, then plunged by 83.15% to $566.2 million in 2023, then tumbled by 71.95% to $158.8 million in 2024, then plunged by 336.63% to -$375.8 million in 2025.
• Business Quant data shows BNTX's EBITDA at -$375.8 million in Q4 2025, -$54.8 million in Q3 2025, and -$567.2 million in Q2 2025.